









Markets
/
Stocks
/
nasdaq-ardx
/

Ardelyx Inc

ARDX

6.265USD

+0.075+1.21%

Market hours （ET）Quotes delayed by 15 min

1.51BMarket Cap

LossP/E TTM



Ardelyx Inc

6.265

+0.075+1.21%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

47 / 507

Overall Ranking

144 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 12 analysts

Buy

Current Rating

11.182

Target Price

+74.17%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 539.62% year-on-year.

Undervalued

The company’s latest PE is -26.42, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 180.23M shares, increasing 3.09% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 15.98M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 8.50, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 97.66M, representing a year-over-year increase of 33.38%, while its net profit experienced a year-over-year increase of 15.95%.

Score

Industry at a Glance

Previous score

8.08

Change

0.42



Financials

6.05

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.75

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.69

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -26.42, which is -41.74% below the recent high of -15.39 and 5.13% above the recent low of -25.07.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 47/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.83, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Ardelyx Inc is 11.00, with a high of 15.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

8.83

Change

Support & Resistance

No Data

Analyst Rating

Based on 12 analysts

Buy

Current Rating

11.182

Target Price

+74.17%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Ardelyx Inc

ARDX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.91, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 6.72 and the support level at 5.72, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.74

Change

-1.83

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.169

Neutral

RSI(14)

53.190

Neutral

STOCH(KDJ)(9,3,3)

19.586

Sell

ATR(14)

0.213

Low Volatility

CCI(14)

-146.954

Sell

Williams %R

88.060

Oversold

TRIX(12,20)

0.856

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

6.486

Sell

MA10

6.531

Sell

MA20

6.381

Sell

MA50

5.453

Buy

MA100

4.708

Buy

MA200

4.955

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 74.79%, representing a quarter-over-quarter increase of 3.00%. The largest institutional shareholder is The Vanguard, holding a total of 15.98M shares, representing 6.63% of shares outstanding, with 9.75% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

15.88M

-3.94%

The Vanguard Group, Inc.

Star Investors

14.94M

+4.44%

Janus Henderson Investors

24.98M

+2.42%

Millennium Management LLC

12.10M

+87.15%

Macquarie Investment Management

11.16M

+7.84%

Marshall Wace LLP

8.38M

+7201.76%

State Street Global Advisors (US)

10.18M

-12.22%

Geode Capital Management, L.L.C.

5.67M

+2.96%

Nuveen LLC

3.39M

+57.47%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.23, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.70. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.